Determination of losartan and hydrochlorothiazide in tablets by CE and CEC
Authors:
- M.G QuagliaMQM.G Quaglia
- E DonatiEDE Donati
- G CarlucciGCG Carlucci
- P MazzeoPMP Mazzeo
- S FanaliSFS Fanali
- 1 August 2002
- journal article
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 29 (6) , 981-987
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Efficacy and safety of losartan in the treatment of hypertension in renal transplant recipientsKidney International, 1998
- A study of losartan, alone or with hydrochlorothiazide vs nifedipine GITS in elderly patients with diastolic hypertensionJournal of Human Hypertension, 1998
- Determination of losartan and its degradates in COZAAR® tablets by reversed-phase high-performance thin-layer chromatographyJournal of Pharmaceutical and Biomedical Analysis, 1998
- Comparison of liquid chromatography, capillary electrophoresis and super-critical fluid chromatography in the determination of Losartan Potassium drug substance in Cozaar® tabletsJournal of Pharmaceutical and Biomedical Analysis, 1996
- Controlled Trial of Losartan Given Concomitantly with Different Doses of Hydrochlorothiazide in Hypertensive PatientsBlood Pressure, 1996
- Absence of a Pharmacokinetic Interaction between Losartan and HydrochlorothiazideThe Journal of Clinical Pharmacology, 1995
- Double-blind comparison of losartan, lisinopril and hydrochlorothiazide in hypertensive patients with a previous angiotensin converting enzyme inhibitor-associated coughJournal Of Hypertension, 1995
- Simultaneous determination of enalapril maleate and hydrochlorothiazide by first-derivative ultraviolet spectrophotometry and high-performance liquid chromatographyJournal of Pharmaceutical and Biomedical Analysis, 1995
- Simultaneous determination of enalapril maleate and hydrochlorothiazide in tablets by derivative UV spectrophotometry and high-performance liquid chromatographyInternational Journal of Pharmaceutics, 1993
- The discovery of DuP 753, a potent, orally active nonpeptide angiotensin II receptor antagonistMedicinal Research Reviews, 1992